To examine the potential effect of RIP1 on the response of melanoma cells to treatment with BRAF/MEK inhibitors, we silenced RIP1 using two individual siRNAs in two BRAFV600E melanoma cell lines (Mel-CV and Mel-RMu) and two wild-type BRAF melanoma cell lines (ME4405 and Mel-RM). Here, RIPK1 is linked to melanoma.